Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
28 March, 2017 15:30 IST
Divis Lab receives import alert for Visakhapatnam facility
Source: IRIS | 21 Mar, 2017, 10.10AM
Comments  |  Post Comment

Divis Laboratories, a pharmaceutical ingredients and intermediates company, has received an Import Alert 66-40 from US Food and Drug Administration (USFDA) for its products manufactured at the company's Unit-II located at Visakhapatnam, Andhra Pradesh on March 20, 2017.

The agency has exempted the following products from the Import Alert-Levetiracetam, Gabapentin, Lamotrigine, Capecitabine, Naproxen sodium, Raltegravir potassium, Atovaquone, Chloropurine, BOC core succinate, 2, 4-wing active ester.

The company along with third party consultants is currently working to address the concerns of the USFDA and is making all efforts to fully meet the compliance requirements. 

Shares of the company declined Rs 138.7, or 17.54%, to trade at Rs 652.00. The total volume of shares traded was 1,228,420 at the BSE (10.02 a.m., Tuesday).



Divis Laboratories Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
ICICI Bank partners with Truecaller to launch UPI based mobile payment service - 28-Mar-2017 13:08
GE Shipping takes delivery of secondhand Suezmax crude carrier 'Jag Lakshya' - 28-Mar-2017 13:04
Indian Oil Corp inks POL supply pact with Nepal Oil Corp - 28-Mar-2017 13:02
Pincon Spirit acquires 100 goods transport vehicles from Tata Motors - 28-Mar-2017 12:58
NTPC gets investment approval for Talaipalli coal mining project - 28-Mar-2017 12:55
Berger Paints commences commercial production at Jejuri plant - 28-Mar-2017 12:53
Bank of Baroda enters into MOU with Jain Irrigation Systems - 28-Mar-2017 12:50
Suven Life Sciences secures overseas product patent - 28-Mar-2017 12:42
Bharti Airtel concludes sale of 10.3% stake in Bharti Infratel - 28-Mar-2017 11:11
Smartlink Network acquires 100% stake in Digisol Systems - 28-Mar-2017 10:44
Aurobindo Pharma receives USFDA approval for Meropenem iniection - 28-Mar-2017 10:33
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer